Ghanbari Hossein, Viatge Helene, Kidane Asmeret G, Burriesci Gaetano, Tavakoli Mehdi, Seifalian Alexander M
Centre for Nanotechnology, Biomaterials and Tissue Engineering, Division of Surgery & Interventional Science, University College London, London, UK.
Trends Biotechnol. 2009 Jun;27(6):359-67. doi: 10.1016/j.tibtech.2009.03.002. Epub 2009 May 4.
Heart valve (HV) replacements are among the most widely used cardiovascular devices and are in rising demand. Currently, clinically available devices are restricted to slightly modified mechanical and bioprosthetic valves. Polymeric HVs could represent an attractive alternative to the existing prostheses, merging the superior durability of mechanical valves and the enhanced haemodynamic function of bioprosthetic valves. After early unsatisfactory clinical results, polymeric HVs did not reach commercialization, mainly owing to their limited durability. Recent advances in polymers, nanomaterials and surface modification techniques together with the emergence of novel biomaterials have resulted in improved biocompatibility and biostability. Advances in HV design and fabrication methods could also lead to polymeric HVs that are suitable for long-lasting implantation. Considering all these progresses, it is likely that the new generation of polymeric HVs will find successful long-term clinical applications in future.
心脏瓣膜（HV）置换是使用最为广泛的心血管器械之一，且需求不断增加。目前，临床可用的器械仅限于经过轻微改良的机械瓣膜和生物假体瓣膜。聚合物心脏瓣膜可能是现有假体的一个有吸引力的替代品，它融合了机械瓣膜的卓越耐用性和生物假体瓣膜增强的血流动力学功能。在早期临床结果不尽人意之后，聚合物心脏瓣膜未能实现商业化，主要是由于其耐久性有限。聚合物、纳米材料和表面改性技术的最新进展以及新型生物材料的出现，提高了生物相容性和生物稳定性。心脏瓣膜设计和制造方法的进步也可能导致适合长期植入的聚合物心脏瓣膜的出现。考虑到所有这些进展，新一代聚合物心脏瓣膜未来有可能在长期临床应用中取得成功。
